
Vanda Pharmaceuticals (VNDA) Stock Forecast & Price Target
Vanda Pharmaceuticals (VNDA) Analyst Ratings
Bulls say
Vanda Pharmaceuticals Inc demonstrates a strong positive outlook based on several key developments, including the expected long-term market exclusivity for milsaperidone, which extends to 2044, supporting sustained revenue growth from its established products. The recent approval and positive clinical results for tradipitant in treating nausea and vomiting associated with GLP-1 receptor agonists indicate significant potential for enhanced compliance and demand in the growing obesity treatment market. Furthermore, the favorable safety profile observed in the NEREUS program for tradipitant underscores the company's commitment to innovative therapies that meet high unmet medical needs, positioning Vanda favorably for future growth and market expansion.
Bears say
Vanda Pharmaceuticals faces several substantial risks that contribute to a negative financial outlook, including slower-than-anticipated sales traction for its key products, Fanapt and Ponvory, and the threat of accelerating generic erosion, particularly impacting Fanapt and Hetlioz. Furthermore, the company is susceptible to negative pricing developments, especially regarding Medicare reimbursement, which may further hinder revenue generation. Additionally, potential regulatory setbacks with late-stage pipeline candidates and adverse clinical readouts raise concerns about the company's ability to achieve growth and maintain shareholder value in the medium to long term.
This aggregate rating is based on analysts' research of Vanda Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Vanda Pharmaceuticals (VNDA) Analyst Forecast & Price Prediction
Start investing in Vanda Pharmaceuticals (VNDA)
Order type
Buy in
Order amount
Est. shares
0 shares